The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Diverse mechanisms of antiepileptic drugs in the development pipeline
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Variations on an inhibitory theme: phasic and tonic activation of GABAA receptors
Farrant, M., & Nusser, Z. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1625 · Cited by 2,081
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1430 · Cited by 1,239
Self-citationBenzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Neuronal KCNQ potassium channels:physislogy and role in disease
Jentsch, T. J. (2000) · Nature Reviews Neuroscience · doi:10.1038/35036198 · Cited by 849
Nusser, Z., Sieghart, W., & Somogyi, P. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01693.1998 · Cited by 833
Stell, B. M., Brickley, S. G., Tang, C. Y., Farrant, M., & Mody, I. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2435457100 · Cited by 797
Perucca, E. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00004 · Cited by 690
Pathways modulating neural KCNQ/M (Kv7) potassium channels
Delmas, P., & Brown, D. A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1785 · Cited by 686
Rogawski, M. A., & Porter, R. J. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00046-8 · Cited by 656
Self-citationPharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & Steve White, H. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 613
Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 K+ channels causes epilepsy
Schroeder, B. C., Kubisch, C., Stein, V., & Jentsch, T. J. (1998) · Nature · doi:10.1038/25367 · Cited by 521
Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
Klitgaard, H., Matagne, A., Gobert, J., & Wülfert, E. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00410-5 · Cited by 506
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions
Rogawski, M. A., & Löscher, W. (2004) · Nature Medicine · doi:10.1038/nm1074 · Cited by 456
Self-citationGenetic absence epilepsy in rats from Strasbourg — A review
Marescaux, C., Vergnes, M., & Depaulis, A. (1992) · Generalized Non-Convulsive Epilepsy: Focus on GABA-B Receptors · doi:10.1007/978-3-7091-9206-1_4 · Cited by 434
Tatulian, L., Delmas, P., Abogadie, F. C., & Brown, D. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05535.2001 · Cited by 406
Enhanced Neurosteroid Potentiation of Ternary GABAAReceptors Containing the δ Subunit
Wohlfarth, K. M., Bianchi, M. T., & Macdonald, R. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01541.2002 · Cited by 393
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Donevan, S. D., & Rogawski, M. A. (1993) · Neuron · doi:10.1016/0896-6273(93)90241-i · Cited by 358
Self-citationKokate, T. G., Svensson, B. E., & Rogawski, M. A. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22531-9 · Cited by 355
Self-citationLöscher, W., Hönack, D., & Rundfeldt, C. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37251-9 · Cited by 343
Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines
Rogawski, M. A. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90005-5 · Cited by 313
Self-citationMechanism of action of the hypnotic zolpidem in vivo
Crestani, F., Martin, J. R., Möhler, H., & Rudolph, U. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703717 · Cited by 307
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.07.010 · Cited by 300
Modulation of KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine
Main, M. J., Cryan, J. E., Dupere, J. R. B., Cox, B., Clare, J. J., & Burbidge, S. A. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12060-3 · Cited by 299
Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects.
Depoortere, H., Zivkovic, B., Lloyd, K. G., Sanger, D. J., Perrault, G., Langer, S. Z., & Bartholini, G. (1986) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24899-6 · Cited by 282
Löscher, W., & Hönack, D. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90768-d · Cited by 281
Reddy, D. S., & Rogawski, M. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03795.2002 · Cited by 279
Self-citationCarter, R. B., Wood, P. L., Wieland, S., Hawkinson, J. E., Belelli, D., Lambert, J. J., White, H. S., Wolf, H. H., Mirsadeghi, S., Tahir, S. H., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36511-5 · Cited by 269
Molecular Determinants of KCNQ (Kv7) K+Channel Sensitivity to the Anticonvulsant Retigabine
Schenzer, A., Friedrich, T., Pusch, M., Saftig, P., Jentsch, T. J., Grötzinger, J., & Schwake, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0128-05.2005 · Cited by 267
Wuttke, T. V., Seebohm, G., Bail, S., Maljevic, S., & Lerche, H. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.010793 · Cited by 262
Carter, R. B., Wood, P. L., Wieland, S., Hawkinson, J. E., Belelli, D., Lambert, J. J., White, H. S., Wolf, H. H., Mirsadeghi, S., Tahir, S. H., et al. (1997) · PubMed · Cited by 251
Rundfeldt, C., & Netzer, R. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00866-1 · Cited by 242
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
Rostock, A., Tober, C., Rundfeldt, C., Bartsch, R., Engel, J., Polymeropoulos, E. E., Kutscher, B., Löscher, W., Hönack, D., White, H. S., et al. (1996) · Epilepsy Research · doi:10.1016/0920-1211(95)00101-8 · Cited by 240
Kenda, B. M., Matagne, A. C., Talaga, P. E., Pasau, P. M., Differding, E., Lallemand, B. I., Frycia, A. M., Moureau, F. G., Klitgaard, H. V., Gillard, M. R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030913e · Cited by 226
Progesterone therapy in women with complex partial and secondary generalized seizures
Herzog, A. G. (1995) · Neurology · doi:10.1212/wnl.45.9.1660 · Cited by 218
ucb L059, a novel anti-convulsant drug: pharmacological profile in animais
Gower, A. J., Noyer, M., Verloes, R., Gobert, J., & Wülfert, E. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90855-x · Cited by 212
Souverein, P. C., Webb, D. J., Petri, H., Weil, J., Van Staa, T. P., & Egberts, T. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.23804.x · Cited by 207
Molecular and Pharmacological Characterization of GABAA Receptor α1 Subunit Knockout Mice
Kralic, J. E., Korpi, E. R., O’Buckley, T. K., Homanics, G. E., & Morrow, A. L. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036665 · Cited by 201
Gower, A. T., Hirsch, E., Boehrer, A., Noyer, M., & Marescaux, C. (1995) · Epilepsy Research · doi:10.1016/0920-1211(95)00077-1 · Cited by 198
Sofia, R. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360423 · Cited by 194
Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188
Rho, J. M., Donevan, S. D., & Rogawski, M. A. (1994) · Annals of Neurology · doi:10.1002/ana.410350216 · Cited by 187
Self-citationDisruption of the Epilepsy KCNQ2 Gene Results in Neural Hyperexcitability
Watanabe, H., Nagata, E., Kosakai, A., Nakamura, M., Yokoyama, M., Tanaka, K., & Sasai, H. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750028.x · Cited by 182
Anticonvulsant Activity of Progesterone and Neurosteroids in Progesterone Receptor Knockout Mice
Reddy, D. S., Castaneda, D. C., O’Malley, B. W., & Rogawski, M. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065268 · Cited by 181
Self-citationKaminski, R. M., Livingood, M. R., & Rogawski, M. A. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.04504.x · Cited by 179
Self-citationThe new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells
Rundfeldt, C. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01249-1 · Cited by 173
Molecular targets versus models for new antiepileptic drug discovery
Rogawski, M. A. (2005) · Epilepsy Research · doi:10.1016/j.eplepsyres.2005.09.012 · Cited by 165
Self-citationZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma
Turski, L., Huth, A., Sheardown, M., McDonald, F., Neuhaus, R., Schneider, H. H., Dirnagl, U., Wiegand, F., Jacobsen, P., & Ottow, E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10960 · Cited by 165
Lambert, J. J., Belelli, D., Harney, S. C., Peters, J. A., & Frenguelli, B. G. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00124-2 · Cited by 164
Kokate, T. G., Banks, M. K., Magee, T., Yamaguchi, S., & Rogawski, M. A. (1999) · PubMed · Cited by 164
Self-citationFinasteride, a 5α-Reductase Inhibitor, Blocks the Anticonvulsant Activity of Progesterone in Mice
Kokate, T. G., Banks, M. K., Magee, T., Yamaguchi, S., & Rogawski, M. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38006-1 · Cited by 163
Self-citationKokate, T. G., Cohen, A. L., Karp, E., & Rogawski, M. A. (1996) · Neuropharmacology · doi:10.1016/s0028-3908(96)00021-4 · Cited by 161
Self-citationLöscher, W., & Nolting, B. (1991) · Epilepsy Research · doi:10.1016/0920-1211(91)90041-d · Cited by 158
Synthesis and Anticonvulsant Activities of N-Benzyl-2-acetamidopropionamide Derivatives
Choi, D., Stables, J. P., & Kohn, H. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9508705 · Cited by 153
Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?
Klitgaard, H. (2001) · Epilepsia · doi:10.1111/j.1528-1167.2001.00003.x · Cited by 153
KCNQ2/KCNQ3 K+ channels and the molecular pathogenesis of epilepsy: implications for therapy
Rogawski, M. A. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01629-5 · Cited by 152
Self-citationProgress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P., & Perucca, E. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(00)00171-6 · Cited by 152
Vainionpää, L. K., Mikkonen, K. H., Rättyä, J., Knip, M., Pakarinen, A., Myllylä, V. V., & Isojärvi, J. I. T. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.26003.x · Cited by 150
Shen, M., Béguin, C., Golbraikh, A., Stables, J. P., Kohn, H., & Tropsha, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030584q · Cited by 150
Reddy, D. S., & Rogawski, M. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39026-3 · Cited by 148
Self-citationDisruption of the epilepsy KCNQ2 gene results in neural hyperexcitability
Watanabe, H. (2000) · Neuroscience Research · doi:10.1016/s0168-0102(00)81544-8 · Cited by 148
New horizons in the development of antiepileptic drugs: Innovative strategies
Löscher, W., & Schmidt, D. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.03.014 · Cited by 147
Yamaguchi, S., Donevan, S. D., & Rogawski, M. A. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90054-b · Cited by 146
Self-citationA Neuropharmacological Evaluation of Felbamate as a Novel Anticonvulsant
White, H. S., Wolf, H. H., Swinyard, E. A., Skeen, G. A., & Sofia, R. D. (1992) · Epilepsia · doi:10.1111/j.1528-1157.1992.tb01711.x · Cited by 142
Benzodiazepines on trial: a research strategy for their rehabilitation
Costa, E., & Guidetti, A. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)10015-8 · Cited by 141
D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures
Tober, C., Rostock, A., Rundfeldt, C., & Bartsch, R. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00073-8 · Cited by 139
Nau, H. (1986) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(86)90180-6 · Cited by 139
Löscher, W., & Nau, H. (1985) · Neuropharmacology · doi:10.1016/0028-3908(85)90028-0 · Cited by 135
Models for Epilepsy and Epileptogenesis: Report from the NIH Workshop, Bethesda, Maryland
Stables, J. P., Bertram, E. H., White, H. S., Coulter, D. A., Dichter, M. A., Jacobs, M. P., Löscher, W., Lowenstein, D. H., Moshé, S. L., Noebels, J. L., et al. (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.06702.x · Cited by 130
Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy
Reddy, D. S., & Rogawski, M. A. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.10200.x · Cited by 130
Self-citationRetigabine: Chemical Synthesis to Clinical Application
Blackburn-Munro, G., Dalby‐Brown, W., Mirza, N. R., Mikkelsen, J. D., & Blackburn-Munro, R. E. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2005.tb00033.x · Cited by 126
AMPA receptors in epilepsy and as targets for antiepileptic drugs.
Rogawski, M. A., & Donevan, S. D. (1999) · PubMed · Cited by 125
Self-citationReddy, D., & Rogawski, M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39152-9 · Cited by 121
Self-citationPitkänen, A., Kharatishvili, I., Narkilahti, S., Łukasiuk, K., & Nissinen, J. (2004) · Epilepsy Research · doi:10.1016/j.eplepsyres.2004.10.003 · Cited by 120
Wickenden, A. D., Krajewski, J. L., London, B., Wagoner, P. K., Wilson, W. A., Clark, S., Roeloffs, R., McNaughton-Smith, G. A., & Rigdon, G. C. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.043216 · Cited by 119
Rundfeldt, C., & Netzer, R. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1300346 · Cited by 118
Tatulian, L., & Brown, D. A. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.039842 · Cited by 113
The GABAA receptor gene family: new opportunities for drug development.
Whiting, P. J. (2003) · PubMed · Cited by 109
Otto, J. F., Kimball, M. M., & Wilcox, K. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.4.921 · Cited by 105
Almeida, L., Falcão, A. C., Maia, J., Mazur, D., Gellert, M., & Soares-da-Silva, P. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005279364 · Cited by 102
Löscher, W., Rundfeldt, C., & Hönack, D. (1993) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1993.tb00224.x · Cited by 99
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells
Wickenden, A. D., Zou, A., Wagoner, P. K., & Jegla, T. J. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703861 · Cited by 97
A crossover, add-on trial of talampanel in patients with refractory partial seizures
Chappell, A. S., Sander, J. W. A. S., Brodie, M. J., Chadwick, D., Lledó, A., Zhang, D., Bjerke, J. S., Kiesler, G. M., & Arroyo, S. (2002) · Neurology · doi:10.1212/wnl.58.11.1680 · Cited by 95
Grabenstatter, H. L., Ferraro, D. J., Williams, P. A., Chapman, P. L., & Dudek, F. E. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.13404.x · Cited by 93
Felbamate block of recombinant N-methyl-d-aspartate receptors: selectivity for the NR2B subunit
Harty, T. P., & Rogawski, M. A. (2000) · Epilepsy Research · doi:10.1016/s0920-1211(99)00108-4 · Cited by 90
Self-citationAsano, T., Mori, T., Shimoda, T., et al. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007053544084 · Cited by 88
Felbamate block of the N-methyl-D-aspartate receptor.
Subramaniam, S., Rho, J. M., Penix, L. P., Donevan, S. D., Fielding, R. P., & Rogawski, M. A. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)09605-3 · Cited by 85
Self-citationKleckner, N. W., Glazewski, J. C., Chen, C. C., & Moscrip, T. D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38215-1 · Cited by 81
Howes, J. F., & Bell, C. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.001 · Cited by 80
New strategies for the identification of drugs to prevent the development or progression of epilepsy
Schmidt, D., & Rogawski, M. A. (2002) · Epilepsy Research · doi:10.1016/s0920-1211(02)00070-0 · Cited by 71
Self-citationIsoherranen, N., Yagen, B., & Bialer, M. (2003) · Current Opinion in Neurology · doi:10.1097/01.wco.0000063774.81810.30 · Cited by 69
Löscher, W., & Hönack, D. (1994) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1994.tb17146.x · Cited by 69
Roeloffs, R., Wickenden, A. D., Crean, C. S., Werness, S., McNaughton-Smith, G. A., Stables, J. P., McNamara, J. O., Ghodadra, N., & Rigdon, G. C. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137794 · Cited by 69
Monaghan, E., McAuley, J., & Data, J. (1999) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.8.10.1663 · Cited by 68
Lack of Anticonvulsant Tolerance to the Neuroactive Steroid Pregnanolone in Mice
Kokate, T. G., Yamaguchi, S.-I., Pannell, L. K., Rajamani, U., Carroll, D. M., Grossman, A. B., & Rogawski, M. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37827-9 · Cited by 68
Self-citationEfficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain
Winkler, I., Blotnick, S., Shimshoni, J. A., Yagen, B., Devor, M. G., & Bialer, M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706310 · Cited by 67
Ionotropic Glutamate Receptors as Therapeutic Targets
Jellinger, K. A. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00786.x · Cited by 67
Comparative anticonvulsant activity of some 2,3-benzodiazepine derivatives in rodents
Sarro, G. D., Ferreri, G., Gareri, P., Russo, E., Sarro, A. D., Gitto, R., & Chimirri, A. (2003) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)01040-7 · Cited by 60
Could Valerian Have Been the First Anticonvulsant?
Eadie, M. J. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.27904.x · Cited by 60
Rogawski, M. A., Kurzman, P. S., Yamaguchi, S.-I., & Li, H. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00112-x · Cited by 56
Self-citationSPD 502: A Water-Soluble and In Vivo Long-Lasting Ampa Antagonist with Neuroprotective Activity
Nielsen, E. Ø., Varming, T., Mathiesen, C., Jensen, L. H., Møller, A., Gouliaev, A. H., Wätjen, F., & Drejer, J. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38297-7 · Cited by 52
Modifying quinolone antibiotics yields new anxiolytics
Johnstone, T. B. C., Hogenkamp, D. J., Coyne, L., Su, J., Halliwell, R. F., Tran, M. B., Yoshimura, R. F., Li, W.-Y., Wang, J., & Gee, K. W. (2003) · Nature Medicine · doi:10.1038/nm967 · Cited by 50
Walters, M. R., Kaste, M., Lees, K. R., Diener, H., Hommel, M., Keyser, J. D., Steiner, H., & Versavel, M. (2005) · Cerebrovascular Diseases · doi:10.1159/000087929 · Cited by 50
Neurosteroids: Endogenous Modulators of Seizure Susceptibility
Rogawski, M. A., & Reddy, D. S. (2004) · Cited by 49
Self-citationTakahashi, M., Ni, J. W., Kawasaki‐Yatsugi, S., Toya, T., Yatsugi, S.-I., Shimizu‐Sasamata, M., Koshiya, K., Shishikura, J., Sakamoto, S., & Yamaguchi, T. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37284-2 · Cited by 49
Takahashi, M., Ni, J. W., Kawasaki‐Yatsugi, S., et al. (1998) · PubMed · Cited by 48
Lees, G., Stöhr, T., & Errington, A. C. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.016 · Cited by 43
Felbamate inhibits cloned voltage-dependent Na+ channels from human and rat brain
Taglialatela, M., Ongini, E., Brown, A. M., Renzo, G. D., & Annunziato, L. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00802-3 · Cited by 43
Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons.
Stefani, A., Calabresi, P., Pisani, A., Mercuri, N. B., Siniscalchi, A., & Bernardi, G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12797-3 · Cited by 43
Hirai, T., Okuma, C., Harada, C., Mio, M., Ohtsu, H., Watanabe, T., & Kamei, C. (2004) · Epilepsia · doi:10.1111/j.0013-9580.2004.19303.x · Cited by 42
Faigle, J. W., & Menge, G. P. (1990) · Behavioural Neurology · doi:10.1155/1990/917164 · Cited by 41
Kuo, C., Lin, B., Chang, H.-R., & Hsieh, C.-P. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.2.370 · Cited by 40
Kume, A., Greenfield, L. J., Macdonald, R. L., & Albin, R. L. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13135-2 · Cited by 38
Langen, B., Egerland, U., Bernöster, K., Dost, R., Unverferth, K., & Rundfeldt, C. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084681 · Cited by 38
(2004) · CRC Press eBooks · doi:10.3109/9780203021934 · Cited by 34
Mechanism-specific pathways for new antiepileptic drug discovery.
Rogawski, M. A. (1998) · PubMed · Cited by 29
Self-citationNeurotherapeutics: Emerging strategies
(1996) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(96)90025-7 · Cited by 24
Dubinsky, B., Vaidya, A. H., Rosenthal, D. I., Hochman, C., Crooke, J. J., DeLuca, S., Devine, A., Cheo-Isaacs, C. T., Carter, A. R., Jordan, A. D., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036954 · Cited by 24
A Psychosocial Approach to Epileptic Patients
Ogata, A., & Amano, K. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb02218.x · Cited by 16
de Paulis, T. (2003) · PubMed · Cited by 14
Cited by
How were new medicines discovered?
Swinney, D. C., & Anthony, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3480 · Cited by 1,812
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 542
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2007) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Molecular Targets for Antiepileptic Drug Development
Meldrum, B. S., & Rogawski, M. A. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.010 · Cited by 468
Self-citationHanada, T., Hashizume, Y., Tokuhara, N., Takenaka, O., Kohmura, N., Ogasawara, A., Hatakeyama, S., Ohgoh, M., Ueno, M., & Nishizawa, Y. (2011) · Epilepsia · doi:10.1111/j.1528-1167.2011.03109.x · Cited by 411
Metadata
- Authors
- Rogawski, M. A.
- Venue
- Epilepsy Research
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 69
- Issue
- 3
- Pages
- 273-294
- ISSN
- 0920-1211 (ISSN-L)
- OpenAlex
- W2086759170
- Cited by
- 340
- References
- 123
- FWCI
- 18.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.